243 filings
Page 6 of 13
8-K
82a 2cb428yw1c
6 Nov 19
CytoSorbents Reports Third Quarter 2019 Financial Results
12:00am
8-K
qu0lc1v
18 Sep 19
Other Events
4:31pm
8-K
eyr0 g3503skj2nuq
16 Sep 19
Regulation FD Disclosure
5:15pm
8-K
nlpeeit
6 Aug 19
CytoSorbents Reports Record Second Quarter 2019 Financial Results
4:43pm
8-K
ybqhscg0f70dmrw7 o8
5 Aug 19
Entry into a Material Definitive Agreement
5:00pm
8-K
3obt2 iyt
5 Aug 19
Departure of Directors or Certain Officers
4:46pm
8-K
wim1 yin8hnm
26 Jul 19
Departure of Directors or Certain Officers
4:30pm
8-K
drdvl
9 Jul 19
Entry into a Material Definitive Agreement
5:28pm
8-K
f0wmjqn2w
13 Jun 19
Amendments to Articles of Incorporation or Bylaws
4:32pm
8-K
2w99jpfzrgryb1x3wl6v
5 Jun 19
Submission of Matters to a Vote of Security Holders
6:06am
8-K
3y8ncmxmw39 dwkq
4 Jun 19
Termination of a Material Definitive Agreement
5:19pm
8-K
ctuy6svnvjuqdjmbtol
8 May 19
CytoSorbents Reports First Quarter 2019 Financial Results and Provides Second Quarter 2019 Guidance
12:00am
8-K
we0oz cm9ksbv
13 Mar 19
CytoSorbents Achieves Record Revenue and Product Sales Growth in 2018
5:20pm
8-K
si1yn 2g7h5
7 Mar 19
Departure of Directors or Certain Officers
12:00am
8-K
gowdnf8 l5s
5 Feb 19
CytoSorbents Announces the Data Safety Monitoring Board Recommends Continuation of REMOVE Endocarditis Trial
4:14pm
8-K
4smtbiybyj6h9x5xf11
24 Jan 19
CytoSorbents Announces Expansion of CytoSorb® Partnership with Fresenius Medical Care
2:21pm
8-K
vkfvo1z84cnmarg
7 Jan 19
CytoSorbents Issues Stockholder Letter with Preliminary 2018 Financial Results
5:11pm
8-K
v0l66jd2p0b hnh9
7 Nov 18
CytoSorbents Reports Third Quarter 2018 Financial Results
5:18pm
8-K
io1wg nib8q8wk1qa
24 Aug 18
Other Events
12:00am
8-K
a8736ai7
3 Aug 18
CytoSorbents Achieves Record Total Revenue and CytoSorb Sales in the Second Quarter 2018
4:30pm